Auro Laboratories reported a 92% jump in net profit to ₹3.53 crore for FY26, driven by a 60% revenue increase. The company also completed a capacity expansion for its anti-diabetic drug, Metformin HCL, doubling production to 3600 MTA.
Auro Laboratories Sees Strong FY26 Growth, Boosted by Capacity Expansion
For the fiscal year ending March 31, 2026, Auro Laboratories reported a significant 92.14% increase in Net Profit After Tax, reaching ₹3.53 crore (₹353.29 lakh), up from ₹1.84 crore (₹183.87 lakh) in the previous year.
Revenue from operations also saw robust growth, climbing 60.74% to ₹30.74 crore (₹3073.98 lakh) from ₹19.12 crore (₹1912.39 lakh) in FY25. Earnings Per Share (EPS) rose by 92.20% to ₹5.67 from ₹2.95.
Reader Takeaway: Strong profit and revenue growth; capacity expansion sets stage for future gains.
What just happened
Auro Laboratories has announced its financial results for the fiscal year 2025-2026, showcasing substantial improvements in profitability and revenue. A key development highlighted is the successful completion of its capacity expansion project for Metformin HCL, a crucial anti-diabetic product. This expansion effectively doubles the production capacity from 1800 MTA to 3600 MTA.
Why this matters
The strong financial performance, particularly the near doubling of net profit and significant revenue growth, indicates enhanced operational efficiency and market demand. The completed capacity expansion for Metformin HCL positions the company to capitalize on future market opportunities and meet increased demand, potentially leading to sustained growth.
The backstory
Auro Laboratories operates within the Bulk Drugs segment. The company has focused on scaling its production capabilities to meet growing healthcare needs, especially for anti-diabetic medications.
What changes now
With the expanded capacity for Metformin HCL online, Auro Laboratories is poised to increase its market share and revenue from this product. Management expects the benefits of this expansion to become more evident in the upcoming financial quarters.
Risks to watch
The company has identified raw material price volatility and competitive pricing pressures from larger Active Pharmaceutical Ingredient (API) suppliers as key risks. Additionally, the Debt-Equity ratio has increased to 1.37 from 1.05 in the previous year, which warrants monitoring.
Peer comparison
While specific peer data is not provided in the filing, the company operates in the competitive API and bulk drug manufacturing sector, where scale and cost efficiency are critical. Larger players may have an advantage in raw material sourcing and pricing power.
Context metrics (time-bound)
As of March 31, 2026, Auro Laboratories employed 78 people. The company's board decided not to propose any dividend for FY26 to prioritize consolidating its financial position. A delay was reported in the appointment of a CFO within SEBI (LODR) Regulations, 2015 timelines, attributed to the candidate search process.
What to track next
Investors will be keen to see how the increased production capacity translates into higher sales volumes and improved margins in subsequent quarters. Monitoring the company's debt levels and its ability to manage raw material price fluctuations will also be crucial.